Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. Its lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. The company also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
IPO Year: 2019
Exchange: NASDAQ
Website: akerotx.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/18/2024 | $65.00 | Buy | Citigroup |
| 4/22/2024 | $30.00 | Neutral | BofA Securities |
| 9/19/2023 | $69.00 | Overweight | Cantor Fitzgerald |
| 8/28/2023 | $83.00 | Buy | UBS |
| 1/27/2023 | $40.00 → $65.00 | Equal-Weight → Overweight | Morgan Stanley |
| 9/14/2022 | $10.00 → $50.00 | In-line → Outperform | Evercore ISI |
| 11/15/2021 | $27.00 → $29.00 | Equal-Weight | Morgan Stanley |
| 11/15/2021 | $64.00 → $62.00 | Buy | HC Wainwright & Co. |
| 10/19/2021 | $27.00 | Overweight → Equal-Weight | Morgan Stanley |
| 9/10/2021 | $40.00 | Buy | BofA Securities |
10-Q - Akero Therapeutics, Inc. (0001744659) (Filer)
8-K - Akero Therapeutics, Inc. (0001744659) (Filer)
10-Q - Akero Therapeutics, Inc. (0001744659) (Filer)
8-K - Akero Therapeutics, Inc. (0001744659) (Filer)
8-K - Akero Therapeutics, Inc. (0001744659) (Filer)
S-3ASR - Akero Therapeutics, Inc. (0001744659) (Filer)
10-Q - Akero Therapeutics, Inc. (0001744659) (Filer)
8-K - Akero Therapeutics, Inc. (0001744659) (Filer)
ARS - Akero Therapeutics, Inc. (0001744659) (Filer)
DEF 14A - Akero Therapeutics, Inc. (0001744659) (Filer)
-- 601 patients have been enrolled in the double-blind portion of the SYNCHRONY Real-World study since initiation in November 2023 -- -- Data from SYNCHRONY Real-World study anticipated in the first half of 2026 -- SOUTH SAN FRANCISCO, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced it has completed enrollment of patients in the double-blind portion of the Phase 3 SYNCHRONY Real-World study of EFX in patients with metabolic dysfunction-associated steatohepatits (MASH) or metabolic dysfunction-asso
SOUTH SAN FRANCISCO, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 11:15 a.m. P.T. A live webcast of the Company presentation will be available through the investor relations section of the Company's website at www.akerotx.com. Following the live webcast, an archived replay will be available on the Company's website. About Akero TherapeuticsAkero Therapeutics is a clinical-stage com
SOUTH SAN FRANCISCO, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will participate in a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference on Tuesday, December 3, 2024, at 9:10 a.m. ET. A live webcast of the Company presentation will be available through the investor relations section of the Company's website at www.akerotx.com. Following the live webcast, an archived replay will be available on the Company's website. About Akero TherapeuticsAkero Therapeutics is
-- Over 40% of participants treated with EFX 50mg for 96 weeks, compared with 0% for placebo, showed regression of liver fibrosis by all of three orthogonal measures: (1) ≥1-stage fibrosis improvement by NASH-CRN stage (conventional histopathology), (2) 30% reduction of liver stiffness by FibroScan® (imaging fibrosis biomarker), and (3) 0.5 point decrease in ELFTM score (serum fibrosis biomarker) – -- Analysis of biopsies by AI-based Digital Pathology (qFibrosis®, Histoindex) corroborated the extent of improvement in fibrosis observed with conventional histopathology after 24 and 96 weeks of EFX treatment, including statistically significant reductions in fibrosis within the perisinusoida
SOUTH SAN FRANCISCO, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will participate in a fireside chat at the Jefferies London Healthcare Conference on Tuesday, November 19, 2024, at 12:00 p.m. GMT. A live webcast of the Company presentation will be available through the investor relations section of the Company's website at www.akerotx.com. Following the live webcast, an archived replay will be available on the Company's website. About Akero TherapeuticsAkero Therapeutics is a c
— First patients dosed in Phase 3 SYNCHRONY Outcomes study of lead candidate efruxifermin (EFX) in patients with compensated cirrhosis (F4) due to MASH — — Phase 3 SYNCHRONY Real-World and Histology studies on track to report results for their respective primary endpoints in 2026 and the first half of 2027 — — Phase 2b SYMMETRY study week 96 results expected to readout in February 2025 — SOUTH SAN FRANCISCO, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including metabolic dysfunction-associated steatohepatiti
-- Oversubscribed financing brings together leading syndicate of life sciences investors -- -- Proceeds to support clinical development of first-in-class therapies for neurological disorders – BOSTON, Oct. 30, 2024 /PRNewswire/ -- Axonis Therapeutics, a biotechnology company focused on the development of novel neuromedicines, announced today the successful completion of an oversubscribed $115 million Series A financing. Proceeds from the financing will be used to advance Axonis' lead development candidate, AXN-027, through clinical proof-of-concept in patients. AXN-027 is a first-in-class oral small molecule designed to potentiate the function of KCC2, a major CNS chloride transporter essent
SOUTH SAN FRANCISCO, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced an upcoming oral presentation and two late-breaking poster presentations at the 75th Annual American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2024 taking place from November 15-19, 2024, in San Diego. The presentations will highlight findings from the 96-week Phase 2b HARMONY study evaluating the efficacy and safety of lead product candidate efruxifermin (EFX) in patients with pre-cirrhotic metabolic d
SOUTH SAN FRANCISCO, Calif., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will participate in a fireside chat at the H.C. Wainwright 8th Annual MASH Virtual Conference on Monday, October 7, 2024, at 11:00 a.m. E.T. A live webcast of the Company presentation will be available through the investor relations section of the Company's website at www.akerotx.com. Following the live webcast, an archived replay will be available on the Company's website. About Akero TherapeuticsAkero Therapeut
Outcomes is the third study in the Phase 3 SYNCHRONY clinical trial program SOUTH SAN FRANCISCO, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today reported the first patient was dosed in the Phase 3 SYNCHRONY Outcomes trial. The study will evaluate the efficacy and safety of EFX for the treatment of compensated cirrhosis, fibrosis stage 4 (F4), due to metabolic dysfunction-associated steatohepatitis (MASH). "Dosing the first patient in the SYNCHRONY Outcomes trial is an exciting milestone that rounds out our
SC 13G/A - Akero Therapeutics, Inc. (0001744659) (Subject)
SC 13G/A - Akero Therapeutics, Inc. (0001744659) (Subject)
SC 13G/A - Akero Therapeutics, Inc. (0001744659) (Subject)
SC 13G/A - Akero Therapeutics, Inc. (0001744659) (Subject)
SC 13G/A - Akero Therapeutics, Inc. (0001744659) (Subject)
SC 13G/A - Akero Therapeutics, Inc. (0001744659) (Subject)
SC 13G/A - Akero Therapeutics, Inc. (0001744659) (Subject)
SC 13G/A - Akero Therapeutics, Inc. (0001744659) (Subject)
SC 13G - Akero Therapeutics, Inc. (0001744659) (Subject)
SC 13G/A - Akero Therapeutics, Inc. (0001744659) (Subject)
4 - Akero Therapeutics, Inc. (0001744659) (Issuer)
4 - Akero Therapeutics, Inc. (0001744659) (Issuer)
-- Initiated Phase 3 SYNCHRONY Outcomes Trial of Lead Candidate Efruxifermin (EFX) in Patients with Compensated Cirrhosis (F4) Due to MASH -- Presented Poster and Late-breaking Oral Presentation on EFX at the EASL Congress 2024 -- -- Leadership Team Expanded with Addition of Scott Gangloff as Chief Technical Officer -- SOUTH SAN FRANCISCO, Calif., Aug. 09, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today reported second quarter financial results for the period ending June 30, 2024 and provided business updates. "The second
SOUTH SAN FRANCISCO, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease, today announced the appointment of Scott Gangloff as Chief Technology Officer. "I am delighted to welcome Scott to Akero. His depth of experience leading drug manufacturing for both national and multi-national biopharmaceutical organizations enriches our company with an invaluable perspective during the late-stage clinical development of efruxifermin," remarked Andrew Cheng, M.D., Ph.D., president and chief executive officer of Akero. "The entire leadership team looks forward to
SOUTH SAN FRANCISCO, Calif., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, today announced the appointment of Patrick Lamy as Senior Vice President, Commercial Strategy. "Akero is thrilled to welcome Patrick to the team, especially following last year's HARMONY study results, which further demonstrate EFX's potential to treat NASH holistically and reverse fibrosis rapidly," said Andrew Cheng, M.D., Ph.D., president and chief executive officer of Akero. "Patrick's extensive experience in liver disease, and commercial stra
SAN DIEGO, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, today announced the appointment of Yuan Xu, Ph.D., to its Board of Directors as an independent director. Dr. Xu brings to Fate Therapeutics over 25 years of discovery, development, manufacturing, and commercial experience in the global biopharmaceuticals business, most recently serving as the Chief Executive Officer and Board Member of Legend Biotech Corporation where she led the company's efforts in advancing ciltacabtagene autoleucel (cilta-cel) from proof-of-concept in 2018 to BLA pr
SOUTH SAN FRANCISCO, Calif., July 14, 2021 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic steatohepatitis (NASH), today announced the appointment of Judy Chou, Ph.D., to its board of directors as an independent director. "Dr. Chou's expertise in biomanufacturing and protein therapeutic development and experience managing regulatory filings and commercial launches make her an asset to our Board," said Andrew Cheng, M.D., Ph.D., president and chief executive officer of Akero Therapeutics. "Akero is fortunate to welcome Dr. Chou and benefit from her strategic insights, particularly
SOUTH SAN FRANCISCO, Calif., April 26, 2021 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic steatohepatitis (NASH), today announced the appointment of Yuan Xu, Ph.D., to its board of directors as an independent director. "Dr. Xu's extensive experience in establishing and leading biopharmaceutical development and manufacturing capabilities brings a complementary perspective to our Board," said Andrew Cheng, M.D., Ph.D., president and chief executive officer of Akero Therapeutics. "The Akero leadership team looks forward to working with Dr. Xu as we enter late-stage development of o
50mg (75%, p<0.001) and 28mg (46%, p=0.07) EFX groups demonstrated ≥1 stage improvement in fibrosis without worsening of MASH, approximately three- and two-fold the placebo rate (24%) 50mg (36%, p<0.01) and 28mg (31%, p<0.01) EFX groups demonstrated ≥2 stage improvement in fibrosis without worsening of MASH, more than 10-fold the placebo rate (3%) EFX-treated patients experienced statistically significant improvements on nearly all histological endpoints by ITT analysis as well as the primary analysis of patients with week 96 biopsies Investor webcast at 8:00 am ET Monday, March 4, 2024 SOUTH SAN FRANCISCO, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics,
SOUTH SAN FRANCISCO, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease, will hold an investor conference on Monday, March 4 at 8:00 a.m. ET to share results after 96 weeks of treatment for its HARMONY study, a double-blind, placebo-controlled Phase 2b study evaluating the efficacy of efruxifermin (EFX) in patients with pre-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH), fibrosis stage 2 or 3 (F2-F3). Conference Call / Webcast DetailsThe company will host a conference call and webcast with slide presentation at 8:00 a.m. ET on Monday
22% (28mg EFX) and 24% (50mg EFX) of patients experienced at least a one-stage improvement in liver fibrosis with no worsening of NASH by week 36, compared to 14% for placebo 4% of patients in each EFX dose group experienced a three- or two-stage reversal of fibrosis with no worsening of NASH, compared to 0% for placebo 63% (28mg EFX) and 60% (50mg EFX) of patients experienced NASH resolution, representing statistically significant differences compared to 26% for placebo Investor webcast at 8:00 a.m. ET to further discuss data SOUTH SAN FRANCISCO, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage company developing transformational treatments
SOUTH SAN FRANCISCO, Calif., Oct. 09, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, will hold an investor conference on Tuesday, October 10 at 8:00 a.m. ET to share topline week 36 results from its SYMMETRY study, a double-blind, placebo-controlled Phase 2b study evaluating the efficacy of efruxifermin (EFX) in patients with compensated cirrhosis due to non-alcoholic steatohepatitis (NASH). The topline results will include histology and changes from baseline in non-invasive measures of fibrosis, glycemic control, and lipoproteins
Patients treated with EFX for 12 weeks combined with GLP-1 achieved a 65% relative reduction in liver fat, compared to a 10% relative reduction for GLP-1 alone 88% of patients treated with EFX combined with GLP-1 had normalized liver fat at week 12, compared with 10% of those treated with GLP-1 alone EFX-treated patients also experienced statistically significant improvements in liver enzymes and noninvasive markers of fibrosis, glycemic control, and lipids Investor webcast at 8:00 am ET today to further discuss data SOUTH SAN FRANCISCO, Calif., June 05, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage company developing transformational treatme
SOUTH SAN FRANCISCO, Calif., June 01, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, will hold an investor conference on Monday, June 5 at 8:00 a.m. ET to share results from Cohort D of the Phase 2b SYMMETRY study. The primary aim of the 12-week study was to assess the safety and tolerability of efruxifermin (EFX) compared to placebo when added to an existing GLP-1 receptor agonist in patients with Type 2 diabetes and F1-F3 liver fibrosis due to NASH. In addition to results for the primary endpoint, the company will present data fo
50mg (41%) and 28mg (39%) groups demonstrated ≥1 stage improvement in fibrosis without worsening of NASH, double the placebo rate (20%) 50mg (76%) and 28mg (47%) groups demonstrated NASH resolution without worsening of fibrosis, three to five times the placebo rate (15%) 50mg (41%) and 28mg (29%) groups demonstrated fibrosis improvement AND resolution of NASH, six to eight times the placebo rate (5%) EFX-treated patients also experienced statistically significant improvements in liver fat, liver enzymes, noninvasive fibrosis markers, glycemic control, lipoproteins, and body weight Investor webcast at 8:00 am ET today to further discuss data SOUTH SAN FRANCISCO, Calif., Sept. 13, 2022
SOUTH SAN FRANCISCO, Calif., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, will hold an investor conference on Tuesday, September 13 at 8:00 a.m. ET to share results from its HARMONY study, a double-blind, placebo-controlled Phase 2b study evaluating the efficacy of efruxifermin (EFX) in patients with pre-cirrhotic non-alcoholic steatohepatitis (NASH), fibrosis stage 2 or 3 (F2-F3). Conference Call / Webcast DetailsThe company will host a conference call and webcast with slide presentation at 8:00 a.m. ET on Tuesday, Se
4 - Akero Therapeutics, Inc. (0001744659) (Issuer)
4 - Akero Therapeutics, Inc. (0001744659) (Issuer)
4 - Akero Therapeutics, Inc. (0001744659) (Issuer)
4 - Akero Therapeutics, Inc. (0001744659) (Issuer)
4 - Akero Therapeutics, Inc. (0001744659) (Issuer)
4 - Akero Therapeutics, Inc. (0001744659) (Issuer)
4 - Akero Therapeutics, Inc. (0001744659) (Issuer)
4 - Akero Therapeutics, Inc. (0001744659) (Issuer)
4 - Akero Therapeutics, Inc. (0001744659) (Issuer)
4 - Akero Therapeutics, Inc. (0001744659) (Issuer)
Citigroup initiated coverage of Akero Therapeutics with a rating of Buy and set a new price target of $65.00
BofA Securities resumed coverage of Akero Therapeutics with a rating of Neutral and set a new price target of $30.00
Cantor Fitzgerald initiated coverage of Akero Therapeutics with a rating of Overweight and set a new price target of $69.00
UBS initiated coverage of Akero Therapeutics with a rating of Buy and set a new price target of $83.00
Morgan Stanley upgraded Akero Therapeutics from Equal-Weight to Overweight and set a new price target of $65.00 from $40.00 previously
Evercore ISI upgraded Akero Therapeutics from In-line to Outperform and set a new price target of $50.00 from $10.00 previously
Morgan Stanley reiterated coverage of Akero Therapeutics with a rating of Equal-Weight and set a new price target of $29.00 from $27.00 previously
HC Wainwright & Co. reiterated coverage of Akero Therapeutics with a rating of Buy and set a new price target of $62.00 from $64.00 previously
Morgan Stanley downgraded Akero Therapeutics from Overweight to Equal-Weight and set a new price target of $27.00
BofA Securities initiated coverage of Akero Therapeutics with a rating of Buy and set a new price target of $40.00